Our core proprietary technologies include our Ultratrace technology and SAAC technology. These technologies drive development of our current portfolio and should enable the research and development of future molecular imaging pharmaceuticals and targeted radiotherapeutic candidates. Our proprietary technologies, applied independently and together, include:

• Ultratrace Technology. Our Ultratrace technology is a proprietary solid-phase radiolabelingtechnology that enables the development of ultrapure radiopharmaceuticals which are devoid of unnecessary cold contaminants, thereby enhancing safety, specificity and potency. Cold contaminants are nonradioactive, or unlabeled targeting molecules, which may potentially induce unnecessary side effects and suboptimize efficacy by competing with radiolabeled targeting molecules for binding to limited numbers of receptor target sites. Current radiolabeling technologies produce radiopharmaceuticals that contain both radiolabeled targeting molecules and unnecessary cold contaminants. We believe that our Ultratrace technology creates meaningful improvements in the detection, monitoring and treatment of disease.


• SAAC Technology. The ability to reliably and robustly incorporate medically useful radioactive metals into biologically relevant targeting molecules is critical to the design of successful radiopharmaceuticals for molecular imaging and targeted radiotherapy. Single Amino Acid Chelate, or SAAC, is our unique metal binding chemistry platform technology. It represents a new family of compounds with superior metal binding properties for leading radionuclides used for imaging and therapy, namely technetium-99m and rhenium-186 and rhenium-188. This technology incorporates a metal binding, or chelating, group that can rapidly and efficiently bind to technetium or rhenium for diagnostic and therapeutic uses with an amino acid portion that allows it to be incorporated into any peptide sequence through the use of conventional peptide chemistry. SAAC offers the potential to create many new compounds that can be screened for molecular targeting of a variety of disease states.


• SAACQ Technology. Two widely employed techniques for visualizing specific biological processes are fluorescence microscopy and radioisotope imaging. Different from current technologies, our new fluorescence-based technology called SAACQ enables the visualization of radiopharmaceuticals interacting with cellular structures. This advance promises to accelerate the development of targeted radiotherapeutics and molecular imaging pharmaceuticals by allowing live cell activity to be viewed by fluorescent microscopy. SAACQ technology may enable our scientists to bridge the gap between research in isolated cells and research in live subjects by increasing the understanding of cellular behavior, potentially resulting in the development of a new generation of targeted radiotherapeutics and molecular imaging pharmaceuticals.


• Nanotrace Discovery. Our Nanotrace Discovery targeting platform technology allows for the rapid creation and screening of new leads for molecular targeting of disease. We believe that we can utilize this technology to create libraries of radiolabeled compounds in a relatively short period of time. These compounds can be more efficiently and effectively screened in cell culture and in animal models than through current screening methods. Nanotrace Discovery appears to be applicable to major disease categories such as cardiovascular disease, oncology and neurology.